{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:52:45Z","timestamp":1791640365376,"version":"4.3.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>\n                    Modulation of RNA and protein expression to restore or normalize neuronal function has emerged as a powerful therapeutic strategy for neurodevelopmental disorders (NDDs) tailoring individual genetic mutations causing intellectual disability (ID), or autism spectrum disorder (ASD), or developmental epileptic encephalopathy (DEE). In recent years, diverse classes of RNA-based molecules have been developed with therapeutic potential, including antisense oligonucleotides (ASOs), oligonucleotides targeting natural antisense transcripts (antagoNATs), Short Interspersed Nuclear Element UP-regulating RNAs (SINEUPs), interfering RNAs (RNAi), Exon-Specific engineering U1 small nuclear RNAs (ExSpeU1s), and small-activating RNA (saRNA) This review highlights the promising advances of these RNA-based therapeutics in addressing syndromic ID, such as Fragile X syndrome,\n                    <jats:italic>MECP2<\/jats:italic>\n                    duplication syndrome,\n                    <jats:italic>FOXG1<\/jats:italic>\n                    -gene related Rett syndrome and Angelman syndrome, which are characterized by well-defined genetic mutations with limited treatment options. Moreover, ASD-related condition linked to mutations in\n                    <jats:italic>CHD8<\/jats:italic>\n                    is under investigation, extending the therapeutic landscape to complex behavioral and cognitive disorders. In the same way, several DEEs caused by mutations in\n                    <jats:italic>CDKL5<\/jats:italic>\n                    ,\n                    <jats:italic>DNM1<\/jats:italic>\n                    ,\n                    <jats:italic>KCNT1, SCN1A<\/jats:italic>\n                    ,\n                    <jats:italic>SCN2A<\/jats:italic>\n                    ,\n                    <jats:italic>SCN8A<\/jats:italic>\n                    , and\n                    <jats:italic>UBA5<\/jats:italic>\n                    genes, which present severe pharmaco-resistant epilepsy, are increasingly becoming targets for RNA molecules that aim to restore neuronal excitability and network function. Together, these findings underscore the expanding therapeutic landscape enabled by RNA technologies, offering unprecedented specificity and flexibility for gene-targeted interventions in NDDs. As the field of RNA medicine continues to evolve across genomics and neuroscience, we aim to provide a resource for researchers and clinicians on promising innovative tools for molecular correction.\n                  <\/jats:p>","DOI":"10.3389\/fmolb.2025.1681647","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:23:34Z","timestamp":1761888214000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["RNA-based therapies for neurodevelopmental disorders: innovative tools for molecular correction"],"prefix":"10.3389","volume":"12","author":[{"given":"Denise","family":"Drongitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Verrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"de Bellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Miano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.ymthe.2020.04.007","article-title":"RNAi-Based gene therapy rescues developmental and epileptic encephalopathy in a genetic mouse model","volume":"28","author":"Aimiuwu","year":"2020","journal-title":"Mol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/15476286.2021.2021650","article-title":"RNA-based therapeutics for neurological diseases","volume":"19","author":"Anthony","year":"2022","journal-title":"RNA Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/hmg\/ddae135","article-title":"Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels","volume":"33","author":"Bajikar","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.3390\/ijms20174130","article-title":"Splicing mutations impairing CDKL5 expression and activity can be efficiently rescued by U1snRNA-Based therapy","volume":"20","author":"Balestra","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8735","DOI":"10.3390\/ijms21228735","article-title":"An exon-specific small nuclear U1 RNA (ExSpeU1) improves hepatic OTC expression in a splicing-defective spf\/ash mouse model of ornithine transcarbamylase deficiency","volume":"21","author":"Balestra","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e146090","DOI":"10.1172\/jci.insight.146090","article-title":"Antisense oligonucleotide therapy for KCNT1 encephalopathy","volume":"7","author":"Burbano","year":"2022","journal-title":"JCI insight"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.3390\/cancers16172940","article-title":"Therapeutic antisense oligonucleotides in oncology: from bench to bedside","volume":"16","author":"\u00c7akan","year":"2024","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eadn8417","DOI":"10.1126\/scitranslmed.adn8417","article-title":"Patient-derived models of UBA5-associated encephalopathy identify defects in neurodevelopment and highlight potential therapeutic avenues","volume":"17","author":"Chen","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.ymthe.2024.02.004","article-title":"Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice","volume":"32","author":"Clarke","year":"2024","journal-title":"Mol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ymthe.2024.12.043","article-title":"SINEUP RNA rescues molecular phenotypes associated with CHD8 suppression in autism spectrum disorder model systems","volume":"33","author":"Di Leva","year":"2025","journal-title":"Mol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"eabf4077","DOI":"10.1126\/scitranslmed.abf4077","article-title":"An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript","volume":"15","author":"Dindot","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1566523211313020009","article-title":"Promotion of cortico-cerebral precursors expansion by artificial pri-miRNAs targeted against the Emx2 locus","volume":"13","author":"Diodato","year":"2013","journal-title":"Curr. gene Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"39311","DOI":"10.1038\/srep39311","article-title":"RNA activation of haploinsufficient Foxg1 gene in murine neocortex","volume":"6","author":"Fimiani","year":"2016","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cells10030591","article-title":"Small activating RNAs: towards the development of new therapeutic agents and clinical treatments","volume":"10","author":"Ghanbarian","year":"2021","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","first-page":"14617","DOI":"10.3390\/ijms241914617","article-title":"Development of Engineered-U1 snRNA therapies: current status","volume":"24","author":"Gon\u00e7alves","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaaz6100","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ana.26861","article-title":"Long-Term downregulation of the sodium channel gene Scn8a is therapeutic in mouse models of SCN8A epilepsy","volume":"95","author":"Hill","year":"2024","journal-title":"Ann. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fncel.2020.00035","article-title":"Transcription and beyond: delineating FOXG1 function in cortical development and disorders","volume":"14","author":"Hou","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1016\/j.ymthe.2024.08.009","article-title":"Effective knockdown-replace gene therapy in a novel mouse model of DNM1 developmental and epileptic encephalopathy","volume":"32","author":"Jones","year":"2024","journal-title":"Mol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e81892","DOI":"10.7554\/eLife.81892","article-title":"Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome","volume":"12","author":"Lee","year":"2023","journal-title":"eLife"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e152079","DOI":"10.1172\/JCI152079","article-title":"Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model","volume":"131","author":"Li","year":"2021","journal-title":"J. Clin. Invest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with Transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2158","article-title":"Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation","volume":"30","author":"Modarresi","year":"2012","journal-title":"Nat. Biotech."},{"key":"B26","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.tins.2020.05.004","article-title":"Neurodevelopmental disorders: from genetics to functional pathways","volume":"43","author":"Parenti","year":"2020","journal-title":"Trends Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"11168","DOI":"10.1038\/ncomms11168","article-title":"Therapeutic activity of modified U1 core spliceosomal particles","volume":"7","author":"Rogalska","year":"2016","journal-title":"Nat. Comm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1090046","DOI":"10.3389\/fcell.2023.1090046","article-title":"Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and saRNA future therapies","volume":"11","author":"Roth","year":"2023","journal-title":"Front. cell Dev. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2302534120","DOI":"10.1073\/pnas.2302534120","article-title":"Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP","volume":"120","author":"Shah","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"eaaz7785","DOI":"10.1126\/scitranslmed.aaz7785","article-title":"Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome","volume":"13","author":"Shao","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/1078-0432.CCR-24-1818","article-title":"AZD8701, an antisense oligonucleotide targeting FOXP3 mRNA, as monotherapy and in combination with durvalumab: a phase I trial in patients with advanced solid tumors","volume":"31","author":"Siu","year":"2025","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"7760556","DOI":"10.1155\/2024\/7760556","article-title":"Characterization and engineered U1 snRNA rescue of splicing variants in a Turkish neurodevelopmental disease cohort","volume":"2024","author":"S\u00f6nmezler","year":"2024","journal-title":"Hum. Mutat."},{"key":"B33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-med-042921-110721","article-title":"Exome\/Genome sequencing in undiagnosed syndromes","volume":"74","author":"Sullivan","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41591-025-03656-0","article-title":"Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy","volume":"31","author":"Wagner","year":"2025","journal-title":"Nat. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/brain\/awad349","article-title":"Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model","volume":"147","author":"Yuan","year":"2024","journal-title":"Brain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/15476286.2015.1060395","article-title":"SINEUPs: a new class of natural and synthetic antisense long non-coding RNAs that activate translation","volume":"12","author":"Zucchelli","year":"2015","journal-title":"RNA Biol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1681647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:23:34Z","timestamp":1761888214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1681647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":36,"alternative-id":["10.3389\/fmolb.2025.1681647"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1681647","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1681647"}}